Intarcia Therapeutics Inc. keeps slipping behind schedule in its quest to submit a new drug application (NDA) for the once- or twice-yearly diabetes drug candidate ITCA 650 to the US FDA, but that hasn’t hampered the private company’s ability to raise money as new and prior investors recently supplied $215m in equity.
Boston-based Intarcia said in May when it reported additional positive results from its four-study Phase III program for ITCA 650...








